Get started
Author

Chisa Kondo

Observed names: C Kondo, C. Kondo, Chisa Kondoh, 近藤 千紗
OpenAlex ID: A5000519458
Antifibrotic effect and long‐term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus
2022 · Taeang Arai, Masanori Atsukawa, et al. · Hepatology Communications · 54
The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study
2019 · Masanori Atsukawa, Akihito Tsubota, et al. · Alimentary Pharmacology & Therapeutics · 52
Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease
2019 · Taeang Arai, Masanori Atsukawa, et al. · Digestive and Liver Disease · 49
Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C
2017 · Masanori Atsukawa, Akihito Tsubota, et al. · Hepatology Research · 45
Relationship between serum vitamin D level and sarcopenia in chronic liver disease
2020 · Tomomi Okubo, Masanori Atsukawa, et al. · Hepatology Research · 43
Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease
2021 · Taeang Arai, Masanori Atsukawa, et al. · Scientific Reports · 39
PDF
Efficacy and safety of oral semaglutide in patients with non‐alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study
2022 · Taeang Arai, Masanori Atsukawa, et al. · JGH Open · 36
Effect of Vitamin D Supplementation on Skeletal Muscle Volume and Strength in Patients with Decompensated Liver Cirrhosis Undergoing Branched Chain Amino Acids Supplementation: A Prospective, Randomized, Controlled Pilot Trial
2021 · Tomomi Okubo, Masanori Atsukawa, et al. · Nutrients · 35
PDF
The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study
2020 · the KTK49 Liver Study Group, Akito Nozaki, et al. · Hepatology International · 35
Prevalence and characteristics of portopulmonary hypertension in cirrhotic patients who underwent both hepatic vein and pulmonary artery catheterization
2020 · Masanori Atsukawa, Akihito Tsubota, et al. · Hepatology Research · 32
Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data
2021 · Taeang Arai, Masanori Atsukawa, et al. · Therapeutic Advances in Endocrinology and Metabolism · 31
Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study
2018 · Masanori Atsukawa, Akihito Tsubota, et al. · Journal of Gastroenterology and Hepatology · 29
Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan
2018 · Hidenori Toyoda, Masanori Atsukawa, et al. · Journal of Gastroenterology · 29
An open‐label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin
2012 · C. Kondo, M. Atsukawa, et al. · Journal of Viral Hepatitis · 27
Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema
2019 · Masanori Atsukawa, Akihito Tsubota, et al. · Journal of Gastroenterology and Hepatology · 25
Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment
2018 · Tomomi Okubo, Masanori Atsukawa, et al. · Hepatology International · 25
Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b
2012 · Masanori Atsukawa, Akihito Tsubota, et al. · Journal of Gastroenterology and Hepatology · 25
Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study
2020 · Masanori Atsukawa, Akihito Tsubota, et al. · Infectious Diseases and Therapy · 24
PDF
Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C
2017 · Masanori Atsukawa, Akihito Tsubota, et al. · Digestive and Liver Disease · 24
Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema
2017 · Masanori Atsukawa, Akihito Tsubota, et al. · Journal of Gastroenterology and Hepatology · 23
Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease
2018 · Taeang Arai, Masanori Atsukawa, et al. · Hepatology Research · 22
Time‐course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis
2021 · Masanori Atsukawa, Akihito Tsubota, et al. · Hepatology Research · 20
Serum Wisteria floribunda agglutinin‐positive Mac‐2 binding protein more reliably distinguishes liver fibrosis stages in non‐alcoholic fatty liver disease than serum Mac‐2 binding protein
2017 · Masanori Atsukawa, Akihito Tsubota, et al. · Hepatology Research · 20
PDF
Predictive factors for improvement of ascites after transjugular intrahepatic portosystemic shunt in patients with refractory ascites
2013 · Yasuhiko Taki, Hidenori Kanazawa, et al. · Hepatology Research · 20
Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients
2016 · Ai Nakagawa, Masanori Atsukawa, et al. · World Journal of Gastroenterology · 19
PDF
Works count: 81
Citation count: 1,140
H-index: 21
I10-index: 43
Year
Topic
Type